Experiment 67910
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | SPADEA,L: BALESTRAZZI,E:. (2001). TREATMENT OF VASCULAR RETINOPATHIES WITH PYCNOGENOL.. 15(3) |
| Amount utilized | |
| Compound isolated | |
| Disease | A CLINICAL TRIAL WHICH CONSISTED OF A DOUBLE-BLIND PHASE IN WHICH 20 PATIENTS WERE RECRUITED AND RANDOMLY TREATED WITH PLACEBO OR PYCNOGENOL (50MGX3/DAY FOR 2 MONTHS0 AND AN OPEN PHASE IN WHICH ANOTHER 20 PATIENTS WERE TREATED WITH PYCONOGENOL AT THE SAME DOSE SCHEDULE. IN TOTAL, 40 PATIENTS WITH DIABETES, ATHEROSCLEROSIS AND OTHER VASCULAR DISEASES INVOLVING THE RETINA WERE ENROLLED; 30 OF THEM WERE TREATED WITH PYCNOGENOL AND 10 WITH PLACEBO. THE RESULTS DEMONSTRATED A BENEFICIAL EFFECT OF PYCNOGENOL ON THE PROGRESSION OF RETINOPATHY. WITHOUT ANY TREATMENT 9PLACEBO) THE RETINOPATHY PROGREWSIVELY WORSENED DURING THE TRIAL AND THE VISUAL ACUITY SIGNIFICANTLY DECREASED; ON THE CONTRAY, THE PYCNOGENOL-TREATED PATIENTS SHOWED NO DETERIORATION OF RETINAL FUNCTION AND A SIGNIFICANT RECOVERY OF VISUAL ACUITY WAS ALSO OBTAINED. THE FLUORANGIOGRAPHY SHOWED AN IMPROVEMENT OF RETINAL VASCULARIZATION AND A REDUCED ENDOTHELIAL PERMEABILITY AND LEAKAGE IN THE PYCNOGENOL, BUT NOT IN THE PLACEBO-TREATED, PATIENTS. THE OPHTHALMOSCOPY AND THE ELECTRORETINOGRAM (ERG) ALSO CONFIRMED THE BENEFICIAL EFFECTS OF PYCNOGENOL. |
| Dose amount | 150.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |